With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...

Stifel Nicolaus analyst Alex Thompson CFA has maintained their bullish stance on VRDN stock, giving a Buy rating yesterday.Stay Ahead of the ...

Viridian Therapeutics, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $27.20. The firm has a market cap of $1.53 billion, a P/E ratio of -4.48 and a beta of 1.04. The company ...

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) were down 3.4% during trading on Tuesday . The stock traded as low as $18.77 and last traded at $19.01. Approximately 81,134 ...

The projected fair value for Viridian Therapeutics is US$14.53 based on 2 Stage Free Cash Flow to Equity Viridian Therapeutics' US$19.31 share price signals that it might be 33% overvalued The ...

The projected fair value for Viridian Therapeutics is US$14.53 based on 2 Stage Free Cash Flow to Equity Viridian Therapeutics' US$19.31 share price signals that it might be 33% overvalued The US$ ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Fintel reports that on December 19, 2024, Wells Fargo downgraded their outlook for Viridian Therapeutics (NasdaqCM:VRDN) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 121.47% ...